Influence of CD4+/CD25 regulatory T cells on atherogenesis in patients with end-stage kidney disease

Expert Review of Cardiovascular Therapy

Volumn 6, Issue 7, 2008, Pages 987-997

  Meier, Pascal ^a   Meier, Rachel ^a   Blanc, Edouard ^a  

^a Hopital de Sion   (Switzerland)

Author keywords

Apoptosis; Atherosclerosis; End stage kidney disease; Immune dysfunction; Oxidized LDL; Reactive oxygen species; Regulatory T cells

Indexed keywords

ATORVASTATIN; CD3 ANTIBODY; CD4 ANTIGEN; CYCLIN A; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; FAS ANTIGEN; GAMMA INTERFERON; HEAT SHOCK PROTEIN 60; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4; INTERLEUKIN 7 RECEPTOR; LEPTIN; LEPTIN RECEPTOR; LOW DENSITY LIPOPROTEIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 3; OXIDIZED LOW DENSITY LIPOPROTEIN; PLACEBO; PROTEIN BAD; PROTEIN BCL XL; TRANSCRIPTION FACTOR FOXP3; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG; CD24 ANTIGEN;

ACUTE CORONARY SYNDROME; ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CD4+ CD25+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CYTOKINE RELEASE; DRUG EFFICACY; DRUG SELECTIVITY; HEART INFARCTION; HEMODIALYSIS; HUMAN; HYPERCHOLESTEROLEMIA; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFLAMMATION; INNATE IMMUNITY; KIDNEY FAILURE; MACROPHAGE; MONOCYTE; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REVIEW; RISK FACTOR; RISK REDUCTION; STROKE; ANIMAL; CHRONIC KIDNEY FAILURE; DRUG EFFECT; IMMUNOLOGY;

ANIMALS; ANTIGENS, CD24; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; KIDNEY FAILURE, CHRONIC; RISK FACTORS; T-LYMPHOCYTES, REGULATORY;

EID: 52049097807     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.6.7.987     Document Type: Review

References (66)

1. + T cell subset in patients with end-stage renal failure. Clin. Nephrol. 63(1), 8-21 (2005).
2. Kronenberg F, Lingenhel A, Neyer U et al. Prevalence of dyslipidemic risk factors in hemodialysis and CAPD patients. Kidney Int. 84(Suppl. 3), S113-S116 (2003).
3. + T cell apoptosis in patients with end-stage renal disease through Fas engagement. J. Am Soc. Nephrol. 18(1), 331-342 (2007).
4. Wanner C, Zimmermann J, Schwedler S, Metzger T. Inflammation and cardiovascular risk in dialysis patients. Kidney Int. 80(Suppl. 3), S99-S102 (2002).
5. Ziouzenkova O, Asatryan L, Akmal M et al. Oxidative cross-linking of ApoB100 and hemoglobin results in low density lipoprotein modification in blood. Relevance to atherogenesis caused by hemodialysis. J. Biol. Chem. 274(27), 18916-18924 (1999).
6. Stemme S, Faber B, Holm J, Wiklund O, Witztum JL, Hansson GK. T lymphocytes from human atherosclerotic plaques recognize oxidized low density lipoprotein. Proc. Natl Acad. Sci. 92(9), 3893-3897 (1995).
7. Hansson GK, Zhou X, Tornquist E, Paulsson G. The role of adaptive immunity in atherosclerosis. Ann. NY Acad. Sci. 902, 53-62 (2000).
8. Benagiano M, Azzurri A, Ciervo A et al. T-helper type 1 lymphocytes drive inflammation in human atherosclerotic lesions. Proc. Natl Acad. Sci. 100(11), 6658-6663 (2003).
9. Libby P. Inflammation in atherosclerosis. Nature 420(6917), 868-874 (2002).
10. + regulatory T cells. Nat. Immunol. 4(4), 330-336 (2003).
11. Ramsdell F. Foxp3 and natural regulatory T cells: key to a cell lineage? Immunity 19(2), 165-168 (2003).
12. Hawrylowicz CM, O'Garra A. Potential role of interleukin-10-secreting regulatory T cells in allergy and asthma. Nat. Rev. Immunol. 5(4), 271-283 (2005).
13. Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat. Immunol. 2(9), 816-822 (2001).
14. + Tregs and immune control. J. Clin. Invest. 114 (9), 1209-1217 (2004).
15. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol. Med. 13(3), 108-116 (2007).
16. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 299 (5609), 1057-1061 (2003).
17. + regulatory T cells by TGF-β induction of transcription factor Foxp3 J. Exp. Med. 198 (12), 1875-1886 (2003).
18. - T cells through Foxp3 induction and down-regulation of Smad7. J Immunol. 172 (23), 5149-5153 (2004).
19. + regulatory T cells J. Immunol. 172 (23), 5986-5993 (2004).
20. Seddiki N, Santner-Nanan B, Martinson J et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 203 (11), 1693-1700 (2004).
21. + Treg cells. J. Exp. Med. 203 (11), 1701-1711 (2006).
22. + immunoregulatory T cells suppress polyclonal T cell activation in vitro by inhibiting interleukin 2 production. J. Exp. Med. 188(2), 287-296 (1998).
23. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N. Engl. J. Med. 352(6), 1685-1695 (2005).
24. Binder CJ, Chang MK, Shaw PX et al. Innate and acquired immunity in atherogenesis. Nat. Med. 8(11), 1218-1226 (2002).
25. + T cells infiltrate lesions of apolipoprotein-E-deficient mice. Am. J. Pathol. 149(2), 359-367 (1996).
26. +) T cells aggravates atherosclerosis in immunodeficient apolipoprotein E knockout mice. Circulation 102(24), 2919-2922 (2000).
27. Taleb S, Tedgui A, Mallat Z. Regulatory T-cell immunity and its relevance to atherosclerosis. J. Intern. Med. 263(5), 489-499 (2008).
28. Kuiper J, van Puijvelde GH, van Wanrooij EJ et al. Immunomodulation of the inflammatory response in atherosclerosis. Curr. Opin. Lipidol. 18(5), 521-526 (2007).
29. Mallat Z, Ait-Oufella H, Tedgui A. Regulatory T-cell immunity in atherosclerosis. Trends Cardiovasc. Med. 17(4), 113-118 (2007).
30. George J, Haratherosclerosis D, Gilburd B et al. Adoptive transfer of β(2)-glycoprotein I-reactive lymphocytes enhances early atherosclerosis in LDL receptor-deficient mice. Circulation 102(15), 1822-1821 (2000).
31. + regulatory T cells in experimental atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27(4), 893-900 (2007).
32. Gotsman I, Grabie N, Gupta R et al. Impaired regulatory T-cell response and enhanced atherosclerosis in the absence of inducible costimulatory molecule. Circulation 114(12), 2047-2055 (2006).
33. Ait-Oufella H, Salomon BL, Porteaux S et al. Natural regulatory T cells control the development of atherosclerosis in mice. Nat. Med. 12(2), 178-180 (2006).
34. + regulatory T cells in patients with acute coronary syndromes. Eur. Heart J. 27(21), 2530-2537 (2006).
35. Smith DA, Irving SD, Sheldon J, Cole D, Kaski JC. Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation 104(7), 746-749 (2001).
36. Heeschen C, Dimmeler S, Hamm CW, Fichtlscherer S, Boersma E, Simoons ML, Zeiher AM. Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation 107(16), 2109-2114 (2003).
37. Tedgui A, Mallat Z. Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol. Rev. 86(5), 515-581 (2006).
38. van Puijvelde GH, van Es T, van Wanrooij EJ et al. Induction of oral tolerance to HSP60 or an HSP60-peptide activates T cell regulation and reduces atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27(12), 2677-2683 (2007).
39. Steffens S, Burger F, Pelli G et al. Short-term treatment with anti-CD3 antibody reduces the development and progression of atherosclerosis in mice. Circulation 114(18), 1977-1984 (2006).
40. Taleb S, Herbin O, Ait-Oufella H et al. Defective leptin/leptin receptor signaling improves regulatory T cell immune response and protects mice from atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 27(12), 2691-2698 (2007).
41. De Rosa V, Procaccini C, Calì G et al. A key role of leptin in the control of regulatory T cell proliferation. Immunity 26(2), 241-255 (2007).
42. Caro JF, Kolaczynski JW, Nyce MR et al. Decreased cerebrospinal-fluid/serum leptin ratio in obesity: a possible mechanism for leptin resistance. Lancet 348(9021), 159-161 (1996).
43. Sharma K, Considine RV, Michael B et al. Plasma leptin is partly cleared by the kidney and is elevated in hemodialysis patients. Kidney Int. 51(6), 1980-1985 (1997).
44. Nordfors L, Lonnqvist F, Heimburger O, Danielsson A, Schalling M, Stenvinkel P. Low leptin gene expression and hyperleptinemia in chronic renal failure. Kidney Int. 54(4), 1267-1275 (1998).
45. Heimburger O, Lonnqvist F, Danielsson A, Nordenstrom J, Stenvinkel P. Serum immunoreactive leptin concentration and its relation to the body fat content in chronic renal failure. J. Am. Soc. Nephrol. 8(9), 1423-1430 (1997).
46. Bossola M, Muscaritoli M, Valenza V et al. Anorexia and serum leptin levels in hemodialysis patients. Nephron Clin. Pract. 97(3), 76-82 (2004).
47. Scholze A, Rattensperger D, Zidek W, Tepel M. Low serum leptin concentration predicts mortality in patients with chronic kidney disease stage 5 on hemodialysis therapy. Obesity 15(6). 1617-1622 (2007).
48. + regulatory T cells protect against injury in an innate murine model of chronic kidney disease. J. Am. Soc. Nephrol. 17(10), 2731-2741 (2006).
49. Prichard SS. Impact of dyslipidemia in end-stage renal disease. J. Am. Soc. Nephrol. 14(Suppl. 4), S315-S320 (2003).
50. Meier P, Dayer E, Blanc E, Wauters JP. Early T cell activation correlates with expression of apoptosis markers in patients with end-stage renal disease. J. Am. Soc. Nephrol. 13(1), 204-212 (2002).
51. Kischkel FC, Hellbardt S, Behrmann I et al. Cytotoxicity-dependent APO-1 (Fas/CD95)-associated proteins form a death-inducing signaling complex (DISC) with the receptor. EMBO J. 14(22), 5579-5588 (1995).
52. Clement MV, Stamenkovic I. Fas and tumor necrosis factor receptor-mediated cell death: similarities and distinctions. J. Exp. Med. 180(2), 557-567 (1994).
53. Peter ME, Kischkel FC, Scheuerpflug CG, Medema JP, Debatin KM, Krammer PH. Resistance of cultured peripheral T cells towards activation-induced cell death involves a lack of recruitment of FLICE (MACH/caspase 8) to the CD95 death-inducing signaling complex. Eur. J. Immunol. 27(5), 1207-1212 (1997).
54. Sata M, Walsh K. Endothelial cell apoptosis induced by oxidized LDL is associated with the down-regulation of the cellular caspase inhibitor FLIP. J. Biol. Chem. 273(50), 33103-33106 (1998).
55. Napoli C, Quehenberger O, De Nigris F, Abete P, Glass CK, Palinski W. Mildly oxidized low density lipoprotein activates multiple apoptotic signaling pathways in human coronary cells. FASEB J. 14(13), 1996-2007 (2000).
56. + regulatory T cell function: IL-2, IL-4, IL-7 and IL-15 preserve optimal suppressive potency in vitro. Int. Immunol. 19(6), 785-799 (2007).
57. Meier P, von Fliedner V, Markert M, van Melle G, Deppisch R, Wauters JP. One-year immunological evaluation of chronic hemodialysis in end-stage renal disease patients. Blood Purif. 18(2), 128-137 (2000).
58. Gomez J, Martinez-A C, Gonzalez A, Garcia A, Rebolk, A. The Bcl-2 gene is differentially regulated by IL-2 and IL-4: role of the transcription factor NF-AT. Oncogene 17(10), 1235-1243 (1998).
59. Lorenz HM, Hieronymus T, Grunke M, Manger B, Kalden JR. Differential role for IL-2 and IL-15 in the inhibition of apoptosis in short-term activated human lymphocytes. Scand. J. Immunol. 45(6), 660-669 (1997).
60. Maron R, Sukhova G, Faria AM et al. Mucosal administration of heat shock protein-65 decreases atherosclerosis and inflammation in aortic arch of low-density lipoprotein receptor-deficient mice. Circulation 106(13), 1708-1715 (2002).
61. George J, Yacov N, Breitbart E et al. Suppression of early atherosclerosis in LDL receptor deficient mice by oral tolerance with β2-glycoprotein I. Cardiovasc. Res. 62(3), 603-609 (2004).
62. George J, Afek A, Gilburd B, Shoenfeld Y, Harats D. Cellular and humoral immune responses to heat shock protein 65 are both involved in promoting fatty-streak formation in LDL-receptor deficient mice. J. Am. Coll. Cardiol. 38(3), 900-905 (2001).
63. Mallat Z, Besnard S, Duriez M et al. Protective role of interleukin-10 in atherosclerosis. Circ. Res. 85(8), e17-e24 (1999).
64. Emeson EE, Shen ML, Bell CG, Qureshi A. Inhibition of atherosclerosis in CD4 T-cell-ablated and nude (nu/nu) C57BL/6 hyperlipidemic mice. Am. J. Pathol. 149(2), 675-685 (1996).
65. + T cells. Atherosclerosis 197(2), 829-839 (2008).
66. Wanner C, Krane V, März W et al. Atorvastatin in patients with Type 2 diabetes mellitus undergoing hemodialysis. N. Engl. J. Med. 353(3), 238-248 (2005).